Every Form 4 that Femasys Inc. (FEMY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FEMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FEMY filings page.
FEMASYS INC director Kenneth D. Eichenbaum received a grant of 880 stock options on June 24, 2026. The options have an exercise price of $3.67 per share, relate to 880 shares of common stock, and vest one year from the grant date assuming continued service. The options expire on June 24, 2036, and following this grant he holds 880 options directly.
FEMASYS INC director Edward R. Uzialko received a grant of 880 stock options on 2026-06-24. Each option has an exercise price of $3.67 and is exercisable for one share of common stock, covering a total of 8,800 underlying shares. The options were granted at no purchase cost and will vest one year from the grant date, assuming continued service, and are scheduled to expire on 2036-06-24. Following this grant, Uzialko holds 880 derivative securities of this type directly.
Femasys Inc. director Alistair Milnes received a new stock option award. On 2026-06-24, he was granted options to acquire 880 shares of Femasys common stock at an exercise price of $3.67 per share, expiring on 2036-06-24. The underlying shares vest one year from the grant date, assuming continued service, and this grant brings his directly held stock options from this award to 880 options.
FEMASYS INC reported that director Charles Larsen received a grant of stock options. The award covers 880 Stock Options (Right to Buy) with an exercise price of $3.67 per share, expiring on June 24, 2036. These options relate to 880 shares of Common Stock and were acquired at a price of $0.00 per option as compensation. According to the company’s disclosure, the shares underlying the option vest one year from the date of grant, assuming continued service. Following this grant, Larsen holds 880 derivative securities of this type directly.
Femasys Inc. executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, acquired equity-linked interests on August 7, 2026. He purchased 3,125 shares of common stock at $3.20 per share for an aggregate $10,000, and received two warrants for 3,125 shares each with a $2.95 exercise price, one immediately exercisable (subject to Nasdaq-related limitations) and one tied to future revenue and stock-price milestones.
FEMASYS INC reported that executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, received a grant of stock options covering 6,250 shares of common stock. The options have an exercise price of $4.08 per share and expire on July 6, 2036. The underlying shares vest in equal installments over four years beginning on July 6, 2027, contingent on continued employment. Following this grant, Mifek holds options for 6,250 shares from this award.
Femasys Inc Chief Technology Officer Jeremy Alexander Sipos reported multiple transactions involving the company’s equity. He purchased 3,125 shares of common stock at $3.20 per share, for an aggregate $10,000, under a Securities Purchase Agreement dated August 7, 2026. On the same date, he was granted a warrant for 3,125 shares of common stock at an exercise price of $2.95 per share, exercisable from August 10, 2026 until August 10, 2029, subject to Nasdaq Capital Market limitations. He also received a milestone warrant for 3,125 shares at $2.95 per share, exercisable only after a future Milestone Date tied to the company achieving $1,500,000 in U.S. revenue in any fiscal quarter and certain stock price conditions; the milestone warrant’s expiration is contingent and not yet determinable.
Femasys Inc. Chief Operating Officer John Charles Canning reported acquiring both common stock and warrants. He purchased 4,375 shares of common stock at $3.20 per share under a Securities Purchase Agreement, resulting in direct ownership of 4,375 common shares. He also received two grants of 4,375 common stock purchase warrants each, with an exercise price of $2.95 per share. One warrant series is exercisable from August 10, 2026 until August 10, 2029, while the milestone warrant becomes exercisable only after a future Milestone Date tied to achieving $1,500,000 in U.S. revenue for any fiscal quarter and meeting specified volume-weighted average price conditions, and is subject to exercise limitations under Nasdaq Capital Market rules.
Femasys Inc. Chief Financial Officer Dov Elefant reported new equity transactions. On August 7, 2026, he purchased 15,625 shares of common stock at $3.20 per share for an aggregate $50,000 under a Securities Purchase Agreement. He also received two direct grants of common stock purchase warrants, each for 15,625 shares at an exercise price of $2.95 per share. One warrant is exercisable from August 10, 2026 until August 10, 2029, subject to Nasdaq Capital Market limitations. The milestone warrant becomes exercisable only after a future Milestone Date tied to achieving $1,500,000 in U.S. quarterly revenue and specified volume-weighted average price conditions.
Femasys Inc. CEO Kathy Lee-Sepsick reported acquiring company securities on August 7, 2026. She purchased 15,625 shares of Common Stock at $3.20 per share, for an aggregate $50,000, under a Securities Purchase Agreement with Femasys and other purchasers. She also received a warrant for 15,625 shares exercisable at $2.95 per share from August 10, 2026 until August 10, 2029, and a separate Milestone warrant for 15,625 shares at the same exercise price, which becomes exercisable only after specified revenue and stock-price conditions are met and is subject to Nasdaq-related exercise limitations.
FEMASYS INC reported that Chief Operating Officer John Charles Canning received a grant of stock options as part of his compensation. The award covers 150,000 options to purchase common stock at an exercise price of $0.38 per share, expiring on March 30, 2036.
The options vest in equal annual installments over four years, beginning on March 30, 2027, and each vesting installment requires that he remain employed by the company or one of its subsidiaries on the applicable vesting date.
Femasys Inc.’s Chief Financial Officer, Dov Elefant, received a grant of 34,122 Series D-1 Warrants on March 19, 2026. The warrants are exercisable into 34,122 shares of common stock at an initial exercise price of $0.58 per share and expire on March 19, 2036.
The award was issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement. Exercise of these warrants is subject to certain limitations under Nasdaq Capital Market rules, which may restrict when and how fully they can be exercised.
Femasys Inc. Chief Executive Officer Kathy Lee-Sepsick received a grant of Series D-1 warrants as a derivative award. She acquired 68,244 Series D-1 warrants on March 19, 2026, each initially exercisable into one share of common stock at an exercise price of $0.58 per share. The warrants are exercisable at her option, subject to Nasdaq Capital Market limitations and adjustment provisions, and expire on March 19, 2036. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement among the company, Lee-Sepsick and other parties.
Femasys Inc. director Charles Larsen received a grant of 34,122 Series D-1 Warrants to acquire common stock. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement dated March 19, 2026. Each warrant has an initial exercise price of $0.58 per share of common stock and is subject to anti-dilution adjustments for events such as stock splits or stock dividends. The holder’s ability to exercise the warrants is limited by Nasdaq Capital Market rules. The warrants are exercisable into 34,122 shares of common stock and expire on March 19, 2036, leaving Larsen holding 34,122 Series D-1 Warrants after this grant.
Femasys Inc. director Kenneth D. Eichenbaum received 102,366 Series D-1 warrants as a non-cash award. These derivative securities allow him to acquire 102,366 shares of common stock at an exercise price of $0.58 per share, exercisable from March 19, 2026 until March 19, 2036. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement and are subject to exercise limitations under Nasdaq Capital Market rules.
Femasys Inc. director Kenneth D. Eichenbaum received a grant of stock options covering 35,200 shares of Common Stock. The options have an exercise price of $0.6000 per share and expire on March 18, 2036. This is a compensation-related award, not an open-market purchase or sale.
The award was reported as a direct holding. According to the footnote, the shares underlying the option will vest in annual one-third increments over a three-year period beginning on March 18, 2027, contingent on continued service. Following this grant, Eichenbaum holds 35,200 derivative securities of this type.
Femasys Inc director reports no new trades. This Form 4 filing lists Joshua Silverman as a director of Femasys Inc but shows no reported transactions in company securities. The transaction summary indicates zero buys, sells, exercises, gifts, or other dispositions, reflecting neutral net trading activity for this period.
Lee-Sepsick Kathy reported acquisition or exercise transactions in this Form 4 filing.
Femasys Inc. reported new equity awards to its CEO, Kathy Lee-Sepsick. On February 19, 2026, she received two grants totaling 729,000 restricted stock units, each representing one share of common stock. One 447,000-unit grant vests in four equal annual installments beginning February 19, 2027, while a 282,000-unit grant fully vests on February 19, 2027, in each case contingent on continued employment.
Femasys Inc. Chief Financial Officer Dov Elefant reported awards of restricted stock units (RSUs) that give him the right to acquire FEMY common shares in the future. He received 173,000 RSUs and 169,000 RSUs, each representing one share when vested. One grant vests in four equal annual installments beginning on February 19, 2027, while the other fully vests on February 19, 2027, in each case contingent on continued employment with the company or a subsidiary on the applicable vesting dates.
Sipos Jeremy Alexander reported acquisition or exercise transactions in this Form 4 filing.
Femasys Inc. Chief Technology Officer Jeremy Alexander Sipos reported an award of 80,000 restricted stock units (RSUs) on February 2, 2026. Each RSU represents a contingent right to receive one share of Femasys (FEMY) common stock.
The 80,000 RSUs were granted at a price of $0 per unit and are held as direct beneficial ownership. The RSUs vest in four equal annual installments beginning on February 2, 2027, as long as Sipos remains employed by Femasys or one of its subsidiaries on each vesting date.
Femasys Inc. (FEMY) disclosed that its Chief Executive Officer and director filed a Form 4 reporting the purchase of derivative securities on 11/07/2025 for an aggregate amount of $50,000.
The reporting person acquired Senior Secured Convertible Notes due 2035, initially convertible at $0.73 per share into up to 68,244 shares of common stock, with the conversion rate subject to standard anti-dilution adjustments and limitations under Nasdaq Capital Market rules. The filing also reports Series A-1, B-1 and C-1 Warrants, each initially exercisable from 11/07/2025 until 11/07/2035 for 68,244 shares of common stock per series, at exercise prices of $0.81, $0.92 and $1.10 per share, respectively, also subject to adjustment and Nasdaq-related limitations.
Femasys Inc. (FEMY) disclosed that a director reported a transaction on 11/07/2025 involving senior secured convertible notes and three warrant series. The reported securities were purchased for an aggregate amount of $25,000.
The notes are convertible at an initial price of $0.73 per share into up to 34,122 shares of common stock, with shares potentially increasing as interest accrues and subject to Nasdaq-related limitations. The Series A-1, Series B-1, and Series C-1 warrants each cover 34,122 shares at initial exercise prices of $0.81, $0.92, and $1.10 per share, respectively. All instruments list an expiration of 11/07/2035 and include customary adjustment provisions for events such as stock splits or dividends.
Femasys Inc. (FEMY) reported an insider transaction by its Chief Financial Officer on a Form 4. On 11/07/2025, the officer acquired Senior Secured Convertible Notes and three warrant series (A-1, B-1, C-1) for an aggregate purchase amount of $25,000.
The notes are initially convertible at $0.73 per share and are linked to up to 34,122 underlying shares based on the original stated amount, with conversion subject to specified limitations. Each of the Series A-1, B-1, and C-1 warrants covers 34,122 underlying shares, became exercisable on 11/07/2025, and expires on 11/07/2035, with initial exercise prices of $0.81, $0.92, and $1.10 per share, respectively. Conversion and exercise terms are adjustable per the instruments’ provisions.